GlassScriptPhysician profile
Rafael Amaro
NPI 1942313218
$6,530.33
in general payments reported to CMS, 2019-2025
38 companies · $888 in 2025
The $888 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $408 · 2021: $716 · 2022: $1,214 · 2023: $1,308 · 2024: $1,469 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,651 · Education: $13.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,651.05 |
| Education | $13.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,274.30 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Celgene Corporation | $569.91 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $475.12 | 2020-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $467.44 | 2019-2024 | Xifaxan |
| Genzyme Corporation | $292.59 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $278.99 | 2021-2023 | Zeposia |
| Madrigal Pharmaceuticals | $231.01 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $226.80 | 2019-2024 | Exalt Model D, X-Tack Endoscopic Helix Tacking System |
| Axonics, INC. | $195.32 | 2022 | |
| Daiichi Sankyo INC. | $171.45 | 2019-2022 | |
| Gilead Sciences, INC. | $117.98 | 2019-2025 | |
| Qol Medical, LLC | $111.44 | 2022-2024 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $94.05 | 2023-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $84.69 | 2019-2024 | Eohilia |
| Merck Sharp & Dohme LLC | $80.17 | 2023 | Dificid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $78.16 | 2021-2024 | Gi Genius |
| Celltrion USA INC. | $77.77 | 2024-2025 | Vegzelma, Zymfentra |
| Nestle Healthcare Nutrition INC. | $64.97 | 2020-2021 | |
| Pharmacosmos Therapeutics INC. | $62.70 | 2021-2022 | |
| Organon LLC | $60.44 | 2022-2025 | Renflexis, Hadlima |
| Pfizer INC. | $60.36 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $60.14 | 2019-2021 | |
| Lilly USA, LLC | $58.98 | 2024 | Omvoh |
| Amag Pharmaceuticals, INC. | $48.63 | 2021 | |
| Allergan, INC. | $45.97 | 2019-2020 | |
| Micro-Tech Endoscopy USA, INC. | $45.31 | 2022-2023 | Blueboost |
| Ucb, INC. | $32.88 | 2019 | |
| Astellas Pharma US INC | $32.84 | 2024 | Vyloy |
| Alfasigma USA, INC. | $29.40 | 2020 | |
| Aimmune Therapeutics, INC. | $21.19 | 2025 | Zenpep |
| Ardelyx, INC. | $19.90 | 2024 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $17.20 | 2021 | |
| Intercept Pharmaceuticals, INC. | $14.56 | 2021 | |
| Braintree Laboratories, INC. | $13.92 | 2020 | |
| Shire North American Group INC | $13.75 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Amaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.